References
- Gordon DS, Jones BM, Browning SW, Spira TJ, Laurence DN. Persistent polyclonal lymphocytosis of B-lymphocytes. N Engl J Med 1982;307:232–236.
- Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Eng J Med 2006;354:899–910.
- Krumbholz M, Meinl I, Kümpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008;71:1350–1354.
- Stüve O, Gold R, Chan A, Mix E, Zettl U, Kieseier BC. α4-Integrin antagonism with natalizumab: effects and adverse effects. J Neurol 2008;255(Suppl. 6):58–65.
- Mouzaki A, Koutsokera M, Dervilli Z, et al. Remitting-relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab. Int J Gen Med 2010;3:313–320.
- Mossafa H, Malaure H, Maynadie M, et al. Persistent polyclonal B lymphocytosis with binucleated lymphocytes: a study of 25 cases. Br J Haematol 1999;104:486–493.
- Cornet E, Lesesve JF, Mossafa H, et al. Long-term follow-up of 111 patients with persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes. Leukemia 2009;23:419–422.
- Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006;13:700–722.
- Roy J, Ryckman C, Bernier V, Whittom R, Delage R. Large cell lymphoma complicating persistent polyclonal B cell lymphocytosis. Leukemia 1998;12:1026–1030.